Taysha Gene Therapies (TSHA) Misses Q4 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/28/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
Taysha Gene Therapies (TSHA) PT Lowered to $31 at Jefferies
April 1, 2022 8:46 AM EDTJefferies analyst Eun Yang lowered the price target on Taysha Gene Therapies (NASDAQ: TSHA) to $31.00 (from $41.00) while maintaining a Buy rating.
The analyst commented, "Prioritization of several key pipeline programs is positive (vs prior >20 gene therapy programs in development),... More
Taysha Gene Therapies (TSHA) PT Lowered to $37 at Oppenheimer
April 1, 2022 8:18 AM EDTOppenheimer analyst Kevin DeGeeter lowered the price target on Taysha Gene Therapies (NASDAQ: TSHA) to $37.00 (from $45.00) while maintaining a Outperform rating.
The analyst commented, "TSHA disclosed restructuring to focus on giant axonal neuropathy (GAN) and Rett syndrome, confirming suggestive comments at our 3/15 conference (note). Restructuring includes:... More
